The CANDY Project

Research project investigating the underlying mechanisms of co-existing neurodevelopmental conditions and epilepsy has kicked-off

For the first time,

experts from the fields of autism, ADHD and epilepsy are joining forces in the European funded project CANDY

CANDY's innovation

is to test, for the first time, if autism, ADHD and ID are caused by a combination of genetic factors and immune activation during ‘sensitive periods’

The CANDY Project

In Europe, 10-15% of children and adults or 50 to 75 million individuals are affected by neurodevelopmental conditions, such as autism, attention-deficit hyperactivity disorder (ADHD), intellectual disability (ID), motor problems and language disorders. It is not hard to imagine that one of these conditions alone can have a serious impact on a person’s life. What makes the situation even worse is the fact that several of these conditions often co-exist and, on top of that, go along with somatic illnesses, such as epilepsy. This significantly affects both life expectancy and quality of life and there are no effective treatments to date.

In the CANDY project, we investigate the biological links between these neurodevelopmental conditions and co-existing somatic illnesses and how treatment and monitoring of affected patients can be improved.

%

of the EU population are affected by Neurodevelopmental Conditions such as autism, ADHD or ID

Autism

People on the autism spectrum experience persistent difficulties with social interaction and communication, display restricted and repetitive behaviour and/or have special circumscribed interests and activities. They often also experience sensory difficulties, such as increased or reduced sensitivity to light, sound, colour, smell, taste or touch.
Read More

ADHD

ADHD belongs also to the group of neurodevelopmental conditions with onset usually occurring in childhood and adolescence. It manifests itself by problems with attention span and self-regulation and/or by impulsivity and high physical restlessness (hyperactivity). A clinical diagnosis is made when persistent symptoms are associated with impairments of functioning at home, school, workplace or during leasure time. However, symptoms alone are not sufficient for a diagnosis.

Read More

ID

Intellectual disability (ID) is characterized by significant limitations both in intellectual functioning (reasoning, learning, problem solving) and in adaptive behavior, which covers a range of everyday social and practical skills. This disability originates before the age of 18.

Read More

Elizabeth Jones

“CANDY will improve our understanding of the overlap and associations between neurodevelopmental conditions and may have an impact on both the guidance for clinical assessment and for preventative and treatment strategies"

Prof. Jan Buitelaar, Coordinator
Radboudumc

Elizabeth Jones

"I want to contribute to a better understanding of neurodevelopmental conditions. I believe this can aid in earlier intervention and finding more fitting support for people with a neurodevelopmental condition"

Ana Praat, Research Assistant
Radboudumc

Elizabeth Jones

"Our team explores immune markers in the context of neurodevelopmental disorders (NDDs) to advance diagnostics and enhance understanding of their pathogenesis."

Dr. Ching-Lien WU, Scientist
INSERM

Elizabeth Jones

"I am very excited about being part of a project that will help us understand the differences and similarities between different childhood onset diagnoses like ASD and ADHD, which is crucial for better individualized interventions in the future. "

Dr. Terje Falck-Ytter, Principle researcher
KIND at Karolinska Institutet

 

Elizabeth Jones

"Most people probably know at least one autistic person in their broader environment. I think that relating my research to what people see in their daily life can definitely make them understand why it is relevant."

Alexandra Abromeit, PhD candidate
RUG

Elizabeth Jones

"CANDY offers a framework to link animal and human data. By testing mice and preschoolers with a developmental delay in a comparable behavioural test battery, we not only advance the mechanistic understanding of the developmental changes in the preschoolers, but also enrich science with the availability of a validated translational test battery "

Prof. Judith Homberg
Radboudumc

Elizabeth Jones

"I want to help, change and improve the identification, diagnosis and care of people with neurodevelopmental disorders. There's still so much to discover and do, it's fascinating!"

Marianne Mercier, Psychologist
APHP

Elizabeth Jones

"My research seeks to obtain detailed mechanistic insights and explores the multivariate mechanisms implicated in autism spectrum conditions to better understand the complexities of this condition."

Alejandro Rivera-Olvera, PhD candidate
RadboudUMC

Elizabeth Jones

"I’m involved in the cognitive tests, the imaging, and the contact with all of our parents. The best thing about testing are the children themselves. They always bring so much energy to the days, no day is the same!"

Sanne Kluin, Research Assistant
RadboudUMC

Elizabeth Jones

"Autistic people are much more likely to have epilepsy than the general population. We hope that this research will pave the way for new and more efficient treatments to address the symptoms of autistic people suffering from epilepsy and improve their quality of life."

Aurélie Baranger, Director
Autism Europe

Elizabeth Jones

"I try to better understand the biological mechanisms that underlie Autism Spectrum Disorders.The ultimate goal of my research is to improve our understanding of sensory symptoms. Hopefully, this can contribute to the improvement of the quality of life for those who are affected by these symptoms."

Iris Riemersma, PhD
RUG

Elizabeth Jones

"It has become increasingly evident that there is tremendous overlap in clinical features between neurodevelopmental and mental health conditions. CANDY helps us to move out of our silos by adopting a transdiagnostic approach."

Eva Loth, Professor
KCL

Partners

European countries

Project duration (months)

Our Research

Read more about the “problem” and the opportunity in CANDY, and more detailed information about biomarkers, the microbiome, neuroinflammation and critical periods. 

FAQs »

Facts & Figures »

The Team »

CANDY PIP Study

In CANDY we are collaborating with the AIMS-2-TRIALS project and their study “Pre-School Brain Imaging and Behaviour Project (PIP)”. PIP is the first study to track how pre-school children with and without autism develop over time and across Europe.

Multiplex Study

This is the first study to track the heritability of rare genetic risk variants for several neurodevelopmental conditions. Neurodevelopmental conditions likely result from a combination of both rare genetic variants and many common low-risk variants.

News & Events

CANDY 4th General Assembly Meeting

CANDY 4th General Assembly Meeting

In January 2023 we finally could meet for our first face-to-face General Assembly Meeting within our CANDY project. This special occasion deservs also a special location: Paris. After 3 years of online and virtual meetings, we were very happy that so many consortium...

read more
Prof Martien Kas is new ECNP President

Prof Martien Kas is new ECNP President

In October 2022, the European College of Neuropsychopharmacology (ECNP) announced within their annual Congress its new ECNP Executive Committee for 2022 - 2025. The commitee is led by Prof Martien Kas from the University of Groningen, who is also part of teh CANDY...

read more
CANDY Publishable Summary #1

CANDY Publishable Summary #1

CANDY has completed its first Periodic Report and its has been approved by our EIC-Project Office. Please find here the publishable summary of the first 18 months of our exciting project. Summary of the context and overall objectives Between 50 to 75 million children...

read more
Load More
Share This